The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
A user's plan to use Zix and topical finasteride (5AR inhibitors) for hair loss, followed by blood testing before/after. The user has suggested creating a fund to cover part of the cost of their blood tests. Replies to their post discuss the effectiveness of the treatments.
The conversation humorously discusses hair loss treatments, including finasteride, minoxidil, and dutasteride. Users joke about side effects and exaggerated results.
The post discusses using ketoconazole and finasteride for hair loss, suggesting waiting to use minoxidil. The user also mentions microneedling and emphasizes confidence over hair appearance.
Minoxidil, finasteride, and RU58841 are discussed as hair loss treatments. Users express skepticism about certain products, with some preferring simpler options like caffeine-based products.
RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.
Different hair loss treatments work for different people, with finasteride and dutasteride generally considered more effective than minoxidil. Combining treatments often yields better results, but individual experiences and side effects vary.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.